Your browser doesn't support javascript.
loading
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault, M; Wehbe, M; Strutt, D; Masin, D; Anantha, M; Walker, D; Chu, F; Backstrom, I; Kalra, J; Waterhouse, D; Yapp, D T; Bally, M B.
Afiliación
  • Verreault M; Brain and Spine Institute Research Center, 47 Bd de l'Hopital, Paris, 75013, France. Electronic address: maiteverreault@gmail.com.
  • Wehbe M; Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, V5Z 1L3, BC, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, Vancouver V6T 1Z3, BC, Canada.
  • Strutt D; Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, V5Z 1L3, BC, Canada.
  • Masin D; Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, V5Z 1L3, BC, Canada.
  • Anantha M; Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, V5Z 1L3, BC, Canada.
  • Walker D; Ultrastructural Imaging, UBC James Hogg Research Laboratories (iCAPTURE), Providence Heart and Lung Institute, St. Paul's Hospital, Rm 166, 1081 Burrard St, Vancouver, BC, Canada.
  • Chu F; Ultrastructural Imaging, UBC James Hogg Research Laboratories (iCAPTURE), Providence Heart and Lung Institute, St. Paul's Hospital, Rm 166, 1081 Burrard St, Vancouver, BC, Canada.
  • Backstrom I; Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, V5Z 1L3, BC, Canada.
  • Kalra J; Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, V5Z 1L3, BC, Canada.
  • Waterhouse D; Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, V5Z 1L3, BC, Canada.
  • Yapp DT; Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, V5Z 1L3, BC, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, Vancouver V6T 1Z3, BC, Canada.
  • Bally MB; Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, V5Z 1L3, BC, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, Vancouver V6T 1Z3, BC, Canada; Department of Pathology and Laboratory Medicine, University of British C
J Control Release ; 220(Pt A): 348-357, 2015 Dec 28.
Article en En | MEDLINE | ID: mdl-26528901
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Camptotecina / Protocolos de Quimioterapia Combinada Antineoplásica / Glioblastoma / Antineoplásicos Alquilantes / Inhibidores de la Angiogénesis / Dacarbazina Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2015 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Camptotecina / Protocolos de Quimioterapia Combinada Antineoplásica / Glioblastoma / Antineoplásicos Alquilantes / Inhibidores de la Angiogénesis / Dacarbazina Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2015 Tipo del documento: Article Pais de publicación: Países Bajos